uniQure Submits AMT-130 for U.S. and U.K. Review
uniQure submitted a Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of ifezuntirgene inilparvovec, formerly AMT-130, for Huntington’s disease and separately submitted a Marketing Authorisation Application to the U.K….
